Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer.

ABSTRACT: Lung cancer (LC) represents the second most diagnosed tumor and the malignancy with the highest mortality rate. In recent years, tremendous progress has been made in the treatment of this tumor thanks to the discovery, testing, and clinical approval of novel therapeutic approaches. Firstly, targeted therapies aimed at inhibiting specific mutated tyrosine kinases or downstream factors were approved in clinical practice. Secondly, immunotherapy inducing the reactivation of the immune system to efficiently eliminate LC cells has been approved. This review describes in depth both current and ongoing clinical studies, which allowed the approval of targeted therapies and immune-checkpoint inhibitors as standard of care for LC. Moreover, the present advantages and pitfalls of new therapeutic appr

SUBMITTER: Leone GM 

PROVIDER: S-EPMC10142433 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature